Search Results - "Germà, J.R."

Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG) by Aparicio, J., Maroto, P., García del Muro, X., Sánchez-Muñoz, A., Gumà, J., Margelí, M., Sáenz, A., Sagastibelza, N., Castellano, D., Arranz, J.A., Hervás, D., Bastús, R., Fernández-Aramburo, A., Sastre, J., Terrasa, J., López-Brea, M., Dorca, J., Almenar, D., Carles, J., Hernández, A., Germà, J.R.

“…We aimed to analyze prognostic factors for relapse in stage I seminoma managed by either active surveillance or adjuvant chemotherapy, and to describe the…”
Get full text

ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor by Juliachs, M., Castillo‐Ávila, W., Vidal, A., Piulats, J.M., Garcia del Muro, X., Condom, E., Hernández‐Losa, J., Teixidó, C., Pandiella, A., Graupera, M., Casanovas, O., Germà, J.R., Villanueva, A., Viñals, F.

“…In this work, we have analyzed the expression of different members of the ErbB family in human samples of testicular germ cell tumors (GCTs). We observed…”
Get full text

The PDGFRβ-AKT Pathway Contributes to CDDP-Acquired Resistance in Testicular Germ Cell Tumors by JULIACHS, M, MUNOZ, C, VINALS, F, MOUTINHO, C. A, VIDAL, A, CONDOM, E, ESTELLER, M, GRAUPERA, M, CASANOVAS, O, GERMA, J. R, VILLANUEVA, A

“…We examined whether PI3K-AKT or extracellular signal-regulated kinase (ERK) signaling pathways could play a role in the development of cisplatin (CDDP)…”
Get full text

894 Generation of Advanced Orthotopic Nude Mice Models of Epithelial Ovarian Cancer and Testicular Germ Cell Tumors for the Study of Cisplatin Resistance and Drug Development by Vidal, A, Piulats, J.M, Vinyals, F, Condom, E, Capella, G, Germa, J.R, Gil-Martín, M, Marti, L, del Muro, F.J. Garcia, Villanueva, A

Get full text

Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM) by Colomer, R., Alba, E., González-Martin, A., Paz-Ares, L., Martín, M., Llombart, A., Rodríguez Lescure, Á., Salvador, J., Albanell, J., Isla, D., Lomas, M., Rodríguez, C.A., Trigo, J.M., Germà, J.R., Bellmunt, J., Tabernero, J., Rosell, R., Aranda, E., Cubedo, R., Baselga, J.

“…Cancer treatment involves the participation of multiple medical specialties and, as our knowledge of the disease increases, this fact becomes even more…”
Get full text

Treatment of malignant superior vena cava syndrome by endovascular stent insertion: Experience on 52 patients with lung cancer by Urruticoechea, A., Mesı́a, R., Domı́nguez, J., Falo, C., Escalante, E., Montes, A., Sancho, C., Cardenal, F., Majem, M., Germà, J.R.

“…Background: Superior vena cava syndrome (SVCS) is a frequent presentation of malignancies involving the mediastinum and can seriously compromise treatment…”
Get full text

7003 A double blind, randomised, dose finding, phase II, multicentre study of radium-223 for the treatment of patients with metastatic castration-refractory prostate cancer (CRPC): EudraCT number: 2005–003680–22 by Parker, C, Hoskin, P, Pascoe, S, Chodack, A, O'Sullivan, J.M, Germá, J.R, Lokna, A

Get full text

Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma by Aparicio, J., García del Muro, X., Maroto, P., Paz-Ares, L., Alba, E., Sáenz, A., Terrasa, J., Barnadas, A., Almenar, D., Arranz, J. A., Sánchez, M., Fernández, A., Sastre, J., Carles, J., Dorca, J., Gumà, J., Yuste, A. L., Germà, J. R.

“…Background: After decades of irradiation as standard therapy for clinical stage I testicular seminoma, alternative treatment approaches have emerged including…”
Get full text

Prognostic value of the expression of E-cadherin and β-catenin in bladder cancer by Garcia del Muro, X., Torregrosa, A., Muñoz, J., Castellsagué, X., Condom, E., Vigués, F., Arance, A., Fabra, A., Germà, J.R.

“…The purpose of this study was to assess the prognostic effect of the expression of E-cadherin, β-catenin and CD44 adhesion molecules in bladder carcinoma. 22…”
Get full text

Impact of new therapies in the treatment of metastatic Castration Resistant Prostate Cancer (CPRCm): Retrospective analysis in a single institution in 2005-2015 by Font, Pous A, Piulats, J, Etxaniz, O, Sala, N, Heras, L, Ferrandiz, U, Garcia, O, Ochoa, M, Barretina, P, Beltran, M, Garcia Del Muro, X, Boladeras, A, Germá, J.R

Get full text

Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer by Oldenburg, J., Aparicio, J., Beyer, J., Cohn-Cedermark, G., Cullen, M., Gilligan, T., De Giorgi, U., De Santis, M., de Wit, R., Fosså, S.D., Germà-Lluch, J.R., Gillessen, S., Haugnes, H.S., Honecker, F., Horwich, A., Lorch, A., Ondruš, D., Rosti, G., Stephenson, A.J., Tandstad, T.

“…Testicular cancer (TC) is the most common neoplasm in males aged 15 to 40 years and approximately 65%–75% have clinical stage I (CSI) disease. Both…”
Get full text

Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study by Psyrri, A., Fortpied, C., Koutsodontis, G., Avgeris, M., Kroupis, C., Goutas, N., Menis, J., Herman, L., Giurgea, L., Remenár, É., Degardin, M., Pateras, I.S., Langendijk, J.A., van Herpen, C.M.L., Awada, A., Germà-Lluch, J.R., Kienzer, H.R., Licitra, L., Vermorken, J.B.

“…EORTC 24971 was a phase III trial demonstrating superiority of induction regimen TPF (docetaxel, cisplatin, 5-fluorouracil) over PF (cisplatin/5-fluorouracil),…”
Get full text

E400P in good prognosis advanced seminoma. The Spanish germ-cell cancer group experience by Arranz, J.A., del Muro, X.García, Gumà, J., Aparicio, J., Salazar, R., Saenz, A., Carles, J., Sánchez, M., Germà, J.R.

Get full text

Clinical Pattern and Therapeutic Results Achieved in 1490 Patients with Germ-Cell Tumours of the Testis: the Experience of the Spanish Germ-Cell Cancer Group (GG) by Germà-Lluch, J.R, Garcia del Muro, X, Maroto, P, Paz-Ares, L, Arranz, J.A, Gumà, J, Alba, E, Sastre, J, Aparicio, J, Fernández, A, Barnadas, A, Terrassa, J, Sáenz, A, Almenar, D, López-Brea, M, Climent, M.A, Sánchez, M.A, Lasso de la Vega, R, Berenguer, G, Pérez, X

“…Objective: To describe the clinical characteristics and treatment results obtained with the application of a homogeneous treatment protocol in 1490 patients…”
Get full text

E 400P in good prognosis advanced seminoma. The Spanish germ-cell cancer group experience by Arranz, J.A., del Muro, X.García, Gumà, J., Aparicio, J., Salazar, R., Saenz, A., Carles, J., Sánchez, M., Germà, J.R.

Get full text

Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours by Maroto, P., del Muro, X. García, Aparicio, J., Paz-Ares, L., Arranz, J. A., Guma, J., Terrassa, J., Barnadas, J., Dorta, J., Germà-Lluch, J. R.

“…Background: The Spanish Germ Cell Group is composed of 60 centres. Our challenge was to define a surveillance protocol that would be safe and suitable…”
Get full text

ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up by Honecker, F., Aparicio, J., Berney, D., Beyer, J., Bokemeyer, C., Cathomas, R., Clarke, N., Cohn-Cedermark, G., Daugaard, G., Dieckmann, K.-P., Fizazi, K., Fosså, S., Germa-Lluch, J.R., Giannatempo, P., Gietema, J.A., Gillessen, S., Haugnes, H.S., Heidenreich, A., Hemminki, K., Huddart, R., Jewett, M.A.S., Joly, F., Lauritsen, J., Lorch, A., Necchi, A., Nicolai, N., Oing, C., Oldenburg, J., Ondruš, D., Papachristofilou, A., Powles, T., Sohaib, A., Ståhl, O., Tandstad, T., Toner, G., Horwich, A.

“…The European Society for Medical Oncology (ESMO) consensus conference on testicular cancer was held on 3–5 November 2016 in Paris, France. The conference…”
Get full text

Alpha-fetoprotein-concanavalin a binding as a marker to discriminate between germ cell tumours and liver diseases by Mora, J., Gascón, N., Tabernero, J.M., Germà, J.R., González, F.

“…In order to differentiate whether slight alpha-fetoprotein (AFP) increases observed in any patient are due to germ cell tumours (GCT) or to liver diseases…”
Get full text

Peripheral blood CD34+ cell immunomagnetic selection in breast cancer patients: effect on hematopoietic progenitor content and hematologic recovery after high-dose chemotherapy and autotransplantation by Cancelas, J.A., Querol, S., Canals, C., Picón, M., Azqueta, C., Solà, C., Montes, A., Amill, B., Griera, E., Inglés, J.R., López, J.J., Germà, J.R., García-López, J.

“…BACKGROUND: Tumor cells have been detected in mobilized peripheral blood of breast cancer patients, and they may contribute to tumor recurrence after the…”
Get full text

1063 The effect of continuing smoking on late relapses and second primary cancers in long-term survivors with small-cell lung cancer (SCLS) by Cardenal, F., Garcia, M., Castellsaguié, X., Garcia del Muro, X., Montes, A., Germà, J.R.

“…From 1981 to 1992, 338 consecutive patients with untreated SCLC received standard therapy at our Institution. Of the 338 patients, 23 (6.8%) were alive and…”
Get full text